Symbols / RADX Stock $4.53 -2.69% Radiopharm Theranostics Limited
RADX (Stock) Chart
About
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
Stock Fundamentals
Scroll to Statements| Market Cap | 35.67M | Enterprise Value | 16.41B | Income | -46.58M | Sales | 16.28M | Book/sh | 3.19 | Cash/sh | 0.01 |
| Dividend Yield | — | Payout | 0.00% | Employees | 14 | IPO | — | P/E | — | Forward P/E | -1.73 |
| PEG | — | P/S | 2.19 | P/B | 1.42 | P/C | — | EV/EBITDA | -418.81 | EV/Sales | 1008.01 |
| Quick Ratio | 3.00 | Current Ratio | 3.01 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -3.79 | EPS next Y | -2.62 |
| EPS Growth | — | Revenue Growth | 154.50% | Earnings | — | ROA | -28.33% | ROE | -92.10% | ROIC | — |
| Gross Margin | -136.51% | Oper. Margin | -4.24% | Profit Margin | -286.16% | Shs Outstand | 7.88M | Shs Float | 2.37B | Short Float | 1.51% |
| Short Ratio | 0.25 | Short Interest | — | 52W High | 16.25 | 52W Low | 3.62 | Beta | 0.84 | Avg Volume | 164.55K |
| Volume | 36.91K | Target Price | $17.88 | Recom | Strong_buy | Prev Close | $4.65 | Price | $4.53 | Change | -2.69% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$17.88
Mean price target
2. Current target
$4.53
Latest analyst target
3. DCF / Fair value
$-47.66
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.53
Low
$12.93
High
$30.74
Mean
$17.88
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-16 | reit | B. Riley Securities | Buy → Buy | $16 |
| 2025-11-26 | main | B. Riley Securities | Buy → Buy | $13 |
| 2025-07-21 | init | Brookline Capital | — → Buy | $18 |
| 2025-05-01 | init | Maxim Group | — → Buy | $12 |
| 2025-03-12 | init | B. Riley Securities | — → Buy | $15 |
- Brain metastases imaging trial completes enrollment; 2 more cancer studies start - Stock Titan hu, 23 Apr 2026 11
- Radiopharm (RADX) Stock Annual Dividend (Bullish Sentiment) 2026-04-20 - Open Stock Signal Network - Cổng thông tin điện tử Tỉnh Sơn La Mon, 20 Apr 2026 06
- Radiopharm Theranostics (NASDAQ: RADX) faces 1.29-quarter cash runway - Stock Titan hu, 23 Apr 2026 12
- Radiopharm (RADX) Sees Slight Pessimism From Analysts - Yahoo Finance Mon, 15 Dec 2025 08
- Radiopharm Theranostics Limited - Depositary Receipt (RADX) price target increased by 752.98% to 39.26 - MSN Sat, 18 Apr 2026 23
- Why Is Radiopharm Theranostics Stock (RADX) Up Today? - TipRanks Mon, 15 Dec 2025 08
- RADX Stock Analysis: Radiopharm Theranostics biotech ADS at 4.32 with minor gain - Cổng thông tin điện tử tỉnh Tây Ninh Wed, 01 Apr 2026 07
- First 3 patients in Radiopharm cancer trial clear path to higher dose - Stock Titan Mon, 20 Apr 2026 11
- Radiopharm Theranostics Limited - Depositary Receipt (RADX) price target decreased by 11.04% to 4.60 - MSN hu, 16 Apr 2026 04
- [6-K] Radiopharm Theranostics Ltd Current Report (Foreign Issuer) | RADX SEC Filing - Form 6-K - Stock Titan Mon, 20 Apr 2026 12
- Radiopharm Theranostics (RADX) director holds 5.33M options at $0.06 - Stock Titan Wed, 01 Apr 2026 07
- Brain metastases scan moves toward Phase 3 with Siemens supply deal - Stock Titan ue, 07 Apr 2026 07
- Brain metastases scan matches MRI in 90% of Radiopharm trial patients - Stock Titan ue, 24 Mar 2026 07
- Radiopharm Theranostics (RADX) director Ian Turner reports share and option holdings - Stock Titan Wed, 01 Apr 2026 07
- Radiopharm Theranostics (RADX) finishes U.S. Phase 2b RAD 101 trial enrollment - Stock Titan hu, 16 Apr 2026 12
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Total Revenue |
|
3.63
+1114.27%
|
0.30
+2.35%
|
0.29
+3210.60%
|
0.01
|
| Operating Revenue |
|
3.63
+1114.27%
|
0.30
+2.35%
|
0.29
+3210.60%
|
0.01
|
| Cost Of Revenue |
|
3.59
|
0.00
|
0.00
|
—
|
| Reconciled Cost Of Revenue |
|
3.59
|
0.00
|
0.00
|
—
|
| Gross Profit |
|
0.04
-86.87%
|
0.30
+2.35%
|
0.29
+3210.60%
|
0.01
|
| Operating Expense |
|
34.68
-7.45%
|
37.47
+17.17%
|
31.98
+60.52%
|
19.93
|
| Research And Development |
|
27.52
+19.18%
|
23.09
+2.01%
|
22.63
+448.68%
|
4.12
|
| Selling General And Administration |
|
16.53
+5.45%
|
15.67
+2.68%
|
15.26
+36.12%
|
11.21
|
| General And Administrative Expense |
|
16.53
+5.45%
|
15.67
+2.68%
|
15.26
+36.12%
|
11.21
|
| Salaries And Wages |
|
12.02
-0.61%
|
12.09
+31.58%
|
9.19
-0.60%
|
9.24
|
| Other Gand A |
|
4.40
+36.64%
|
3.22
-40.19%
|
5.39
+173.65%
|
1.97
|
| Other Operating Expenses |
|
-9.37
-624.80%
|
-1.29
+78.16%
|
-5.92
-468.28%
|
1.61
|
| Total Expenses |
|
38.27
+2.14%
|
37.47
+17.17%
|
31.98
+60.52%
|
19.93
|
| Operating Income |
|
-34.64
+6.81%
|
-37.17
-17.30%
|
-31.69
-59.12%
|
-19.92
|
| Total Operating Income As Reported |
|
-38.17
+19.14%
|
-47.21
-36.89%
|
-34.49
|
—
|
| EBITDA |
|
-38.17
+19.14%
|
-47.20
-36.90%
|
-34.48
-91.95%
|
-17.96
|
| Normalized EBITDA |
|
-34.23
+6.84%
|
-36.75
-16.52%
|
-31.54
-86.24%
|
-16.93
|
| Reconciled Depreciation |
|
0.01
-2.69%
|
0.01
+14.97%
|
0.01
-99.78%
|
2.98
|
| EBIT |
|
-38.17
+19.14%
|
-47.21
-36.89%
|
-34.49
-64.66%
|
-20.94
|
| Total Unusual Items |
|
-3.93
+62.39%
|
-10.45
-255.37%
|
-2.94
-186.00%
|
-1.03
|
| Total Unusual Items Excluding Goodwill |
|
-3.93
+62.39%
|
-10.45
-255.37%
|
-2.94
-186.00%
|
-1.03
|
| Special Income Charges |
|
-4.07
+61.42%
|
-10.55
-292.96%
|
-2.68
|
—
|
| Impairment Of Capital Assets |
|
—
|
1.48
-52.29%
|
3.10
|
—
|
| Restructuring And Mergern Acquisition |
|
4.07
-54.07%
|
8.86
+230.08%
|
2.68
|
—
|
| Net Income |
|
-38.34
+20.04%
|
-47.95
-38.54%
|
-34.61
-14.08%
|
-30.34
|
| Pretax Income |
|
-38.24
+20.09%
|
-47.85
-38.41%
|
-34.57
-14.12%
|
-30.29
|
| Net Non Operating Interest Income Expense |
|
0.33
+247.60%
|
-0.23
-482.88%
|
0.06
+100.63%
|
-9.35
|
| Interest Expense Non Operating |
|
0.07
-89.84%
|
0.64
+646.75%
|
0.09
-99.08%
|
9.35
|
| Net Interest Income |
|
0.33
+247.60%
|
-0.23
-482.88%
|
0.06
+100.63%
|
-9.35
|
| Interest Expense |
|
0.07
-89.84%
|
0.64
+646.75%
|
0.09
-99.08%
|
9.35
|
| Interest Income Non Operating |
|
0.89
+1659.36%
|
0.05
-65.19%
|
0.15
|
—
|
| Interest Income |
|
0.89
+1659.36%
|
0.05
-65.19%
|
0.15
|
—
|
| Other Income Expense |
|
-3.93
+62.39%
|
-10.45
-255.37%
|
-2.94
-186.00%
|
-1.03
|
| Other Non Operating Income Expenses |
|
—
|
-7.57
-227.89%
|
5.92
+675.36%
|
-1.03
|
| Gain On Sale Of Security |
|
0.14
+45.47%
|
0.09
+136.91%
|
-0.26
+74.99%
|
-1.03
|
| Tax Provision |
|
0.10
+7.19%
|
0.10
+153.56%
|
0.04
-14.40%
|
0.04
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-1.18
+62.39%
|
-3.14
-255.37%
|
-0.88
-186.00%
|
-0.31
|
| Net Income Including Noncontrolling Interests |
|
-38.34
+20.04%
|
-47.95
-38.54%
|
-34.61
-14.08%
|
-30.34
|
| Net Income From Continuing Operation Net Minority Interest |
|
-38.34
+20.04%
|
-47.95
-38.54%
|
-34.61
-14.08%
|
-30.34
|
| Net Income From Continuing And Discontinued Operation |
|
-38.34
+20.04%
|
-47.95
-38.54%
|
-34.61
-14.08%
|
-30.34
|
| Net Income Continuous Operations |
|
-38.34
+20.04%
|
-47.95
-38.54%
|
-34.61
-14.08%
|
-30.34
|
| Normalized Income |
|
-35.59
+12.41%
|
-40.63
-24.82%
|
-32.55
-9.90%
|
-29.62
|
| Net Income Common Stockholders |
|
-38.34
+20.04%
|
-47.95
-38.54%
|
-34.61
-14.08%
|
-30.34
|
| Diluted EPS |
|
-5.28
+85.82%
|
-37.23
-16.08%
|
-32.07
+30.05%
|
-45.85
|
| Basic EPS |
|
-5.28
+85.82%
|
-37.23
-16.08%
|
-32.07
+30.05%
|
-45.85
|
| Basic Average Shares |
|
6.94
+438.49%
|
1.29
+19.35%
|
1.08
+63.12%
|
0.66
|
| Diluted Average Shares |
|
6.95
+439.62%
|
1.29
+19.35%
|
1.08
+63.12%
|
0.66
|
| Diluted NI Availto Com Stockholders |
|
-38.34
+20.04%
|
-47.95
-38.54%
|
-34.61
|
—
|
| Amortization |
|
—
|
3.12
-5.20%
|
3.29
+10.39%
|
2.98
|
| Amortization Of Intangibles Income Statement |
|
—
|
3.12
-5.20%
|
3.29
+10.39%
|
2.98
|
| Depreciation Amortization Depletion Income Statement |
|
0.01
-2.69%
|
0.01
+14.97%
|
0.01
-99.78%
|
2.98
|
| Depreciation And Amortization In Income Statement |
|
0.01
-2.69%
|
0.01
+14.97%
|
0.01
-99.78%
|
2.98
|
| Depreciation Income Statement |
|
0.01
-2.69%
|
0.01
+14.97%
|
0.01
+459.61%
|
0.00
|
| Gain On Sale Of PPE |
|
0.00
+100.00%
|
-1.69
|
0.00
|
—
|
| Insurance And Claims |
|
0.11
-70.56%
|
0.36
-47.59%
|
0.69
|
—
|
| Total Other Finance Cost |
|
0.49
+233.56%
|
-0.37
|
—
|
—
|
| Line Item | Trend | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Total Assets |
|
86.48
+20.05%
|
72.04
-3.89%
|
74.95
-10.11%
|
83.38
|
| Current Assets |
|
39.85
+74.43%
|
22.85
+40.17%
|
16.30
-40.21%
|
27.26
|
| Cash Cash Equivalents And Short Term Investments |
|
29.12
+56.75%
|
18.58
+58.77%
|
11.70
-56.64%
|
26.98
|
| Cash And Cash Equivalents |
|
29.12
+56.75%
|
18.58
+58.77%
|
11.70
-56.64%
|
26.98
|
| Cash Financial |
|
29.12
+56.75%
|
18.58
+58.77%
|
11.70
-56.64%
|
26.98
|
| Receivables |
|
10.40
+953.26%
|
0.99
-77.90%
|
4.47
+7810.32%
|
0.06
|
| Accounts Receivable |
|
—
|
0.80
+666.88%
|
0.10
+85.38%
|
0.06
|
| Gross Accounts Receivable |
|
—
|
0.80
+666.88%
|
0.10
+85.38%
|
0.06
|
| Other Receivables |
|
0.23
+23.91%
|
0.18
-95.77%
|
4.36
|
—
|
| Taxes Receivable |
|
10.17
+1166.71%
|
0.80
|
—
|
—
|
| Assets Held For Sale Current |
|
0.00
-100.00%
|
3.00
|
—
|
—
|
| Other Current Assets |
|
0.34
+16.96%
|
0.29
+116.49%
|
0.13
-41.82%
|
0.23
|
| Total Non Current Assets |
|
46.63
-5.20%
|
49.19
-16.13%
|
58.65
+4.51%
|
56.12
|
| Net PPE |
|
0.05
-12.06%
|
0.06
-11.02%
|
0.07
+4230.16%
|
0.00
|
| Gross PPE |
|
—
|
0.06
-11.02%
|
0.07
+4230.16%
|
0.00
|
| Machinery Furniture Equipment |
|
—
|
0.06
-11.02%
|
0.07
+4230.16%
|
0.00
|
| Goodwill And Other Intangible Assets |
|
46.57
-5.12%
|
49.09
-16.15%
|
58.54
+4.40%
|
56.08
|
| Other Intangible Assets |
|
46.57
-5.12%
|
49.09
-16.15%
|
58.54
+4.40%
|
56.08
|
| Investments And Advances |
|
0.00
-100.00%
|
0.04
|
—
|
—
|
| Other Non Current Assets |
|
—
|
0.04
+0.00%
|
0.04
+0.00%
|
0.04
|
| Total Liabilities Net Minority Interest |
|
43.61
-2.40%
|
44.68
+52.14%
|
29.37
+43.84%
|
20.42
|
| Current Liabilities |
|
14.93
-15.04%
|
17.58
+32.86%
|
13.23
+67.91%
|
7.88
|
| Payables And Accrued Expenses |
|
9.34
-13.96%
|
10.86
+112.07%
|
5.12
+137.75%
|
2.15
|
| Payables |
|
6.59
-28.18%
|
9.18
+79.24%
|
5.12
+137.75%
|
2.15
|
| Accounts Payable |
|
6.35
-1.35%
|
6.43
+117.64%
|
2.96
+148.52%
|
1.19
|
| Other Payable |
|
0.24
-91.14%
|
2.74
+26.76%
|
2.16
+124.45%
|
0.96
|
| Current Accrued Expenses |
|
2.75
+63.69%
|
1.68
|
—
|
—
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.45
+12.59%
|
0.40
+38.32%
|
0.29
+210.31%
|
0.09
|
| Current Deferred Liabilities |
|
1.72
-26.97%
|
2.36
|
—
|
—
|
| Current Deferred Revenue |
|
1.72
|
0.00
|
—
|
—
|
| Other Current Liabilities |
|
3.42
-13.67%
|
3.96
-49.32%
|
7.82
+38.86%
|
5.63
|
| Total Non Current Liabilities Net Minority Interest |
|
28.68
+5.79%
|
27.11
+67.94%
|
16.14
+28.72%
|
12.54
|
| Tradeand Other Payables Non Current |
|
0.00
|
0.00
-100.00%
|
0.17
+10.99%
|
0.15
|
| Non Current Deferred Liabilities |
|
0.00
|
0.00
|
—
|
—
|
| Other Non Current Liabilities |
|
28.68
+5.79%
|
27.11
+69.72%
|
15.97
+28.94%
|
12.39
|
| Stockholders Equity |
|
44.79
+59.27%
|
28.12
-36.64%
|
44.38
-29.51%
|
62.96
|
| Common Stock Equity |
|
44.79
+59.27%
|
28.12
-36.64%
|
44.38
-29.51%
|
62.96
|
| Capital Stock |
|
176.56
+75.36%
|
100.68
+3.55%
|
97.23
+12.07%
|
86.76
|
| Common Stock |
|
176.56
+75.36%
|
100.68
+3.55%
|
97.23
+12.07%
|
86.76
|
| Share Issued |
|
2,364.95
+413.71%
|
460.37
+28.14%
|
359.27
+28.41%
|
279.77
|
| Ordinary Shares Number |
|
2,364.95
+413.71%
|
460.37
+28.14%
|
359.27
+28.41%
|
279.77
|
| Retained Earnings |
|
-145.73
-30.89%
|
-111.34
-70.36%
|
-65.35
-112.02%
|
-30.82
|
| Gains Losses Not Affecting Retained Earnings |
|
13.12
-65.42%
|
37.93
+266.07%
|
10.36
+47.43%
|
7.03
|
| Minority Interest |
|
-1.92
-149.60%
|
-0.77
-164.38%
|
1.19
|
—
|
| Other Equity Adjustments |
|
13.12
-65.42%
|
37.93
+266.07%
|
10.36
+47.43%
|
7.03
|
| Total Equity Gross Minority Interest |
|
42.87
+56.73%
|
27.35
-39.99%
|
45.58
-27.61%
|
62.96
|
| Total Capitalization |
|
44.79
+59.27%
|
28.12
-36.64%
|
44.38
-29.51%
|
62.96
|
| Working Capital |
|
24.92
+372.66%
|
5.27
+71.69%
|
3.07
-84.16%
|
19.39
|
| Invested Capital |
|
44.79
+59.27%
|
28.12
-36.64%
|
44.38
-29.51%
|
62.96
|
| Net Tangible Assets |
|
-1.78
+91.50%
|
-20.96
-48.09%
|
-14.16
-305.55%
|
6.89
|
| Tangible Book Value |
|
-1.78
+91.50%
|
-20.96
-48.09%
|
-14.16
-305.55%
|
6.89
|
| Available For Sale Securities |
|
—
|
0.04
|
—
|
—
|
| Foreign Currency Translation Adjustments |
|
—
|
-0.54
|
—
|
—
|
| Investmentin Financial Assets |
|
0.00
-100.00%
|
0.04
|
—
|
—
|
| Other Equity Interest |
|
0.85
+0.00%
|
0.85
-60.42%
|
2.15
|
—
|
| Line Item | Trend | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Investing Cash Flow |
|
1.77
+653.31%
|
-0.32
+79.09%
|
-1.53
+94.60%
|
-28.37
|
| Cash Flow From Continuing Investing Activities |
|
1.77
+653.31%
|
-0.32
+79.09%
|
-1.53
+94.60%
|
-28.37
|
| Net PPE Purchase And Sale |
|
0.00
|
0.00
+100.00%
|
-0.05
-1548.09%
|
-0.00
|
| Purchase Of PPE |
|
0.00
|
0.00
+100.00%
|
-0.05
-1548.09%
|
-0.00
|
| Capital Expenditure |
|
—
|
—
|
-1.53
+94.60%
|
-28.34
|
| Net Intangibles Purchase And Sale |
|
3.00
|
0.00
+100.00%
|
-1.49
+94.76%
|
-28.34
|
| Purchase Of Intangibles |
|
—
|
—
|
-1.49
+94.76%
|
-28.34
|
| Net Other Investing Changes |
|
-1.23
-283.44%
|
-0.32
|
—
|
-0.04
|
| Financing Cash Flow |
|
45.43
+50.45%
|
30.20
+227.59%
|
9.22
-85.84%
|
65.11
|
| Cash Flow From Continuing Financing Activities |
|
45.43
+50.45%
|
30.20
+227.59%
|
9.22
-85.84%
|
65.11
|
| Net Issuance Payments Of Debt |
|
-1.90
-186.28%
|
2.20
|
0.00
+100.00%
|
-0.06
|
| Issuance Of Debt |
|
0.00
-100.00%
|
7.37
|
0.00
-100.00%
|
0.01
|
| Repayment Of Debt |
|
-1.90
+63.23%
|
-5.17
|
0.00
+100.00%
|
-0.07
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
7.37
|
0.00
-100.00%
|
0.01
|
| Long Term Debt Payments |
|
-1.90
+63.23%
|
-5.17
|
0.00
+100.00%
|
-0.07
|
| Net Long Term Debt Issuance |
|
-1.90
-186.28%
|
2.20
|
0.00
+100.00%
|
-0.06
|
| Net Common Stock Issuance |
|
53.98
+82.08%
|
29.65
+194.32%
|
10.07
-85.61%
|
70.00
|
| Common Stock Payments |
|
—
|
-1.53
-79.44%
|
-0.85
+82.31%
|
-4.83
|
| Repurchase Of Capital Stock |
|
—
|
-1.53
-79.44%
|
-0.85
+82.31%
|
-4.83
|
| Net Other Financing Charges |
|
-6.65
-302.62%
|
-1.65
-93.13%
|
-0.85
+82.31%
|
-4.83
|
| Changes In Cash |
|
10.56
+52.97%
|
6.90
+144.48%
|
-15.51
-157.84%
|
26.82
|
| Effect Of Exchange Rate Changes |
|
-0.01
+40.59%
|
-0.03
-110.67%
|
0.23
+84.22%
|
0.13
|
| Beginning Cash Position |
|
18.58
+58.77%
|
11.70
-56.64%
|
26.98
+99486.97%
|
0.03
|
| End Cash Position |
|
29.12
+56.75%
|
18.58
+58.77%
|
11.70
-56.64%
|
26.98
|
| Free Cash Flow |
|
-36.65
-59.50%
|
-22.98
+7.10%
|
-24.73
+35.35%
|
-38.25
|
| Cash Flowsfromusedin Operating Activities Direct |
|
-36.65
-59.50%
|
-22.98
+0.97%
|
-23.20
-133.99%
|
-9.92
|
| Classesof Cash Payments |
|
-42.80
-52.10%
|
-28.14
-11.69%
|
-25.19
|
—
|
| Classesof Cash Receiptsfrom Operating Activities |
|
5.35
+4.73%
|
5.11
+176.71%
|
1.85
+118.63%
|
-9.92
|
| Common Stock Issuance |
|
53.98
+82.08%
|
29.65
+194.32%
|
10.07
-85.61%
|
70.00
|
| Interest Received CFI |
|
—
|
—
|
—
|
0.01
|
| Interest Received Direct |
|
0.80
+1485.27%
|
0.05
-65.19%
|
0.15
|
—
|
| Issuance Of Capital Stock |
|
53.98
+82.08%
|
29.65
+194.32%
|
10.07
-85.61%
|
70.00
|
| Other Cash Paymentsfrom Operating Activities |
|
—
|
4.85
+211.98%
|
1.56
|
—
|
| Other Cash Receiptsfrom Operating Activities |
|
—
|
4.85
+211.98%
|
1.56
|
—
|
| Paymentsto Suppliersfor Goodsand Services |
|
-42.80
-52.10%
|
-28.14
-11.69%
|
-25.19
|
—
|
| Receiptsfrom Customers |
|
5.35
+1955.57%
|
0.26
-10.91%
|
0.29
+102.95%
|
-9.92
|
| Taxes Refund Paid Direct |
|
0.00
-100.00%
|
4.85
+211.98%
|
1.56
|
—
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|